{"id":816778,"date":"2025-02-24T10:40:39","date_gmt":"2025-02-24T15:40:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/"},"modified":"2025-02-24T10:40:39","modified_gmt":"2025-02-24T15:40:39","slug":"evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/","title":{"rendered":"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOLANA BEACH, Calif., Feb.  24, 2025  (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI<sup>\u00ae<\/sup> (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke\u2019s commercial strategy and growth potential.<\/p>\n<p>Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commercial Officer at Aytu BioPharma, a Nasdaq-listed company specializing in the commercialization of prescription products, where he has played a pivotal role in driving the company to operational profitability. Under his leadership, Aytu has strengthened its financial performance and achieved sustainable revenue growth over the past two years. His expertise in expanding prescription product revenues and optimizing commercial operations has contributed to Aytu\u2019s continued financial momentum.<\/p>\n<p>\u201cWe are excited to welcome Greg to our Board of Directors,\u201d said Matt D&#8217;Onofrio, CEO of Evoke Pharma. \u201cHis deep expertise in commercial strategy and revenue optimization, coupled with his success in driving robust financial performance, aligns perfectly with Evoke\u2019s ongoing growth trajectory. As we continue expanding access to Gimoti<sup>\u00ae<\/sup>, Greg\u2019s insights will be instrumental in helping us strengthen our market presence and enhance shareholder value.\u201d<\/p>\n<p>Prior to Aytu, he held senior commercial leadership roles at Neos Therapeutics, including Vice President, Commercial Strategy &amp; Market Access, and Vice President, Commercial. Over his 20-year career, he has built and led high-performing teams across sales, brand management, managed markets, and business development. His career also includes leadership positions at Aqua Pharmaceuticals (an Almirall company), Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.<\/p>\n<p>Mr. Pyszczymuka commented, \u201cI am honored to join Evoke\u2019s Board of Directors at this exciting time. Evoke\u2019s commitment to addressing the needs of patients with diabetic gastroparesis resonates deeply with me, and I look forward to leveraging my experience to help drive commercial success. With Gimoti<sup>\u00ae<\/sup> gaining market traction, I see tremendous opportunities to further expand adoption and accelerate growth.\u201d<\/p>\n<p>\n        <strong>About Evoke Pharma, Inc.<\/strong>\n      <\/p>\n<p>Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.<\/p>\n<p>Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.<\/p>\n<p>Visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0ZuIVQ0_t5RgkY7wRRG-D-HBMYd1_Nb4AsZtw2FmcwHCUxKjZcDsT5Fd3cP5aFGWxk_84Q7sVUy6Dz2y44l733HuruPwjkavh3T8YjT_dWg=\" rel=\"nofollow\" target=\"_blank\">www.EvokePharma.com<\/a>\u00a0for more information.<\/p>\n<p>Follow\u00a0Evoke Pharma\u00a0on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=taThCG8pxMd3hAW6SgkUkjkuT8-s-YAV0l_MOFlXLKsNvd02ufSEXLTSVQV8GPaQ7F_lSxUdhWH3L9KOrlUZoR7a7_yHkX3C7XtBWxp7x4cr3a6clkJ8zMokeFw0x65YISQ3eQRuN-E7hIiOUPSglg==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a><br \/>Follow\u00a0Evoke Pharma\u00a0on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VzlkIp_6qRxJ2Lgi5R9v2qEFtuBULGHiPO4x9ssOOja6O_dGQLkFaQWJq3Kmqv9QwWj-4RS4jKcCJKHmPZqPEg==\" rel=\"nofollow\" target=\"_blank\">Twitter<\/a><\/p>\n<p>\n        <strong>Safe Harbor Statement<\/strong>\n      <\/p>\n<p>Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negatives of these terms or other similar expressions. These statements are based on the company\u2019s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke\u2019s or EVERSANA\u2019s marketing efforts; Evoke\u2019s commercialization plans, the potential market opportunity for GIMOTI, Evoke\u2019s\u00a0partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoke\u2019s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke\u2019s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke\u2019s and EVERSANA\u2019s ability to successfully drive market demand for GIMOTI; Evoke\u2019s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke\u2019s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke\u2019s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke\u2019s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>Investor &amp; Media Contact:<\/strong>\n      <\/p>\n<p>Daniel Kontoh-Boateng<\/p>\n<p>DKB Partners<\/p>\n<p>Tel: 862-213-1398<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hB8o908pAGwK3nMK_yY3tH98mBvPHgn5bbodzMPtVGWfk7B6VmfK6C0kFQR1qMX4R4zC8nWGNN8I6amML66hBg6ONKtMKaXoRFCEdcmARSo=\" rel=\"nofollow\" target=\"_blank\">dboateng@dkbpartners.net<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGFlNzgxYTktNDEzNi00Yzk0LTg1NDMtOGUzYjU2YWQ1ZDA1LTEwMzgyNTM=\/tiny\/Evoke-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke\u2019s commercial strategy and growth potential. Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commercial Officer at Aytu BioPharma, a Nasdaq-listed company specializing in the commercialization of prescription products, where he has played a pivotal role in driving the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816778","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke\u2019s commercial strategy and growth potential. Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commercial Officer at Aytu BioPharma, a Nasdaq-listed company specializing in the commercialization of prescription products, where he has played a pivotal role in driving the &hellip; Continue reading &quot;Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T15:40:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors\",\"datePublished\":\"2025-02-24T15:40:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/\"},\"wordCount\":932,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/\",\"name\":\"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=\",\"datePublished\":\"2025-02-24T15:40:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - Market Newsdesk","og_description":"SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI\u00ae (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke\u2019s commercial strategy and growth potential. Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commercial Officer at Aytu BioPharma, a Nasdaq-listed company specializing in the commercialization of prescription products, where he has played a pivotal role in driving the &hellip; Continue reading \"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T15:40:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors","datePublished":"2025-02-24T15:40:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/"},"wordCount":932,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/","name":"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=","datePublished":"2025-02-24T15:40:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzIzMiM2Nzc0NTkxIzIwMjc2OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evoke-pharma-announces-the-appointment-of-greg-pyszczymuka-to-the-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816778"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816778\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}